Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 3 Hematologic and non-hematologic toxic events

From: Predictive significance of FGFR4 p.G388R polymorphism in metastatic colorectal cancer patients receiving trifluridine/tipiracil (TAS-102) treatment

Toxicity

No

%

Alopecia

  

 G1/G2

8

17.0

 G3

2

4.3

Anemia

  

 G1/G2

21

44.7

 G3

5

10.6

AST/ALT increase

  

 G1/G2

8

17.0

 G3

2

4.3

Fatigue

  

 G1/G2

26

55.3

 G3

8

17.0

Diarrhea

  

 G1/G2

22

46.8

 G3

4

8.5

Nausea/Vomiting

  

 G1/G2

18

38.3

 G3

1

2.1

Neutropenia

  

 G1/G2

18

38.3

 G3

14

29.8

 G4

2

4.2

Stomatitis

  

 G1/G2

18

38.3

 G3

2

4.2

Thrombocytopenia

  

 G1/G2

9

19.1

 G3

2

4.2